NXTC
NextCure, Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.48
−12.18%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$6.16
From 52W high−61.60%
Volume66800.00
Market cap$25.08M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$6.16
From 52W high
−61.60%
Volume
66800.00
Market cap
$25.08M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.2x
P/E (TTM)
—
RSI (14)
46.6
MomentumView details →
1D Return
−12.18%
YTD Return
−59.48%
SummaryUpdated Jun 1, 2026
NextCure, Inc. (NASDAQ:NXTC) is a clinical-stage biopharmaceutical company founded in 2015 and headquartered in Beltsville, Maryland. The company went public in May 2019 and focuses on discovering and developing novel immunotherapies to treat cancer and other immune-related diseases. NextCure's approach centers on restoring normal immune function through targeted immunomodulation, representing a specialized segment within the broader cancer immunotherapy field.
Similar companies
Latest newsMore news →
NextCure, Inc. amended its lease agreement, accelerating the lease expiration to December 31, 2027, terminating rent obligations as of September 1, 2026, and paying a lump sum of $758,648 while forfeiting a $39,292.70 security deposit.46d agoXcellon Biologics acquires a GMP manufacturing facility from NextCure, becoming an end-to-end CRDMO for next-generation bioconjugates and complex biologics.70d agoAvere, an investee of Hansoh Pharmaceutical, merges into NextCure via a merger agreement, with Hansoh expected to hold more than 30% of the combined entity's equity.97d ago